Molecular alterations associated with osteosarcoma development

Sarcoma

Volumn 2012, Issue , 2012, Pages

  Ando, Kosei ^a,b,c   Mori, Kanji ^d   Verrecchia, Franck ^a,b   Marc, Baud'Huin ^a,b,e   Rédini, Françoise ^a,b,c,e   Heymann, Dominique ^a,b,c,e  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Equipe Labellisee LIGUE 2012   (France)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^e NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; BETA CATENIN; CHEMOKINE RECEPTOR CXCR3; DASATINIB; DISULFIRAM; IMATINIB; INTERLEUKIN 12; INTERLEUKIN 18; OCTREOTIDE; RECOMBINANT ENDOSTATIN; SARACATINIB; SOMATOMEDIN C; SORAFENIB;

APOPTOSIS; BASEMENT MEMBRANE; CANCER INVASION; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CHEMOSENSITIVITY; CHRONIC MYELOID LEUKEMIA; CIRCULATION; DORMANCY; DRUG EFFICACY; EXTRACELLULAR MATRIX; HUMAN; LUNG METASTASIS; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; TISSUE REPAIR; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; WOUND HEALING;

EID: 84858121164     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2012/523432     Document Type: Review

References (182)

1. Meyers P. A., Gorlick R., Osteosarcoma Pediatric Clinics of North America 1997 44 4 973 989 (Pubitemid 27368674)
2. Rosen G., Caparros B., Huvos A. G., Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy Cancer 1982 49 6 1221 1230 (Pubitemid 12187826)
3. Bacci G., Longhi A., Cesari M., Versari M., Bertoni F., Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients Cancer 2006 106 12 2701 2706
4. Bruland O. S., Pihl A., On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy European Journal of Cancer 1997 33 11 1725 1731 (Pubitemid 28129196)
5. Longhi A., Errani C., De Paolis M., Mercuri M., Bacci G., Primary bone osteosarcoma in the pediatric age: state of the art Cancer Treatment Reviews 2006 32 6 423 436 (Pubitemid 44309249)
6. Heymann D., Rédini F., Bone sarcomas: pathogenesis and new therapeutic approaches IBMS 2011 8 9 402 414
7. Heymann D., Bone cancer: progression and therapeutic approaches 2010 Academic Press
8. Bacci G., Ferrari S., Longhi A., Perin S., Forni C., Fabbri N., Salduca N., Versari M., Smith K. V. J., Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy European Journal of Cancer 2001 37 1 32 38 (Pubitemid 32119357)
9. Dunn D., Dehner L. P., Metastatic osteosarcoma to lung: a clinicopathologic study of surgical biopsies and resections Cancer 1977 40 6 3054 3064
10. Enneking W. F., Spanier S. S., Goodman M. A., A system for the surgical staging of musculoskeletal sarcoma Clinical Orthopaedics and Related Research 1980 153 106 120 (Pubitemid 11217753)
11. Folkman J., The role of angiogenesis in tumor growth Seminars in Cancer Biology 1992 3 2 65 71
12. Thompson W. D., Shiach K. J., Fraser R. A., Tumours acquire their vasculature by vessel incorporation, not vessel ingrowth Journal of Pathology 1987 151 4 323 332 (Pubitemid 17071726)
13. Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Susan Harvey V., Dvorak H. F., Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 1983 219 4587 983 985
14. Leung D. W., Cachianes G., Kuang W. J., Goeddel D. V., Ferrara N., Vascular endothelial growth factor is a secreted angiogenic mitogen Science 1989 246 4935 1306 1309 (Pubitemid 20066716)
15. Eccles S. A., Welch D. R., Metastasis: recent discoveries and novel treatment strategies The Lancet 2007 369 9574 1742 1757 (Pubitemid 46755391)
16. Steeg P. S., Tumor metastasis: mechanistic insights and clinical challenges Nature Medicine 2006 12 8 895 904 (Pubitemid 44175140)
17. Kaplan R. N., Psaila B., Lyden D., Bone marrow cells in the pre-metastatic niche: within bone and beyond Cancer and Metastasis Reviews 2006 25 4 521 529 (Pubitemid 46071861)
18. Dan K., Andreasen P. A., Grndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L., Plasminogen activators, tissue degradation, and cancer Advances in Cancer Research 1985 44 139 266
19. Georges S., Ruiz Velasco C., Trichet V., Fortun Y., Heymann D., Padrines M., Proteases and bone remodelling Cytokine and Growth Factor Reviews 2009 20 1 29 41
20. Bergers G., Brekken R., McMahon G., Vu T. H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D., Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis Nature Cell Biology 2000 2 10 737 744
21. Iozzo R. V., Zoeller J. J., Nystrm A., Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis Molecules and Cells 2009 27 5 503 513
22. Lee Y. H., Tokunaga T., Oshika Y., Suto R., Yanagisawa K., Tomisawa M., Fukuda H., Nakano H., Abe S., Tateishi A., Kijima H., Yamazaki H., Tamaoki N., Ueyama Y., Nakamura M., Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma European Journal of Cancer 1999 35 7 1089 1093 (Pubitemid 29339192)
23. Kaya M., Wada T., Akatsuka T., Kawaguchi S., Nagoya S., Shindoh M., Higashino F., Mezawa F., Okada F., Ishii S., Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis Clinical Cancer Research 2000 6 2 572 577 (Pubitemid 30111481)
24. Franchi A., Arganini L., Baroni G., Calzolari A., Capanna R., Campanacci D., Caldora P., Masi L., Brandi M. L., Zampi G., Expression of transforming growth factor isoforms in osteosarcoma variants: association of TGF 1 with high-grade osteosarcomas Journal of Pathology 1998 185 3 284 289 (Pubitemid 28320050)
25. Scotlandi K., Picci P., Kovar H., Targeted therapies in bone sarcomas Current Cancer Drug Targets 2009 9 7 843 853
26. Abdeen A., Chou A. J., Healey J. H., Khanna C., Osborne T. S., Hewitt S. M., Kim M., Wang D., Moody K., Gorlick R., Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma Cancer 2009 115 22 5243 5250
27. Mantadakis E., Kim G., Reisch J., McHard K., Maale G., Leavey P. J., Timmons C., Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma Journal of Pediatric Hematology/Oncology 2001 23 5 286 289 (Pubitemid 32662036)
28. Mikulic D., Ili I., epuli M., Orli D., Giljevi J. S., Fattorini I., Seiwerth S., Tumor angiogenesis and outcome in osteosarcoma Pediatric Hematology and Oncology 2004 21 7 611 619 (Pubitemid 39336818)
29. Kreuter M., Bieker R., Bielaek S. S., Auras T., Buerger H., Gosheger G., Jurgens H., Berdel W. E., Mesters R. M., Prognostic relevance of increased angiogenesis in osteosarcoma Clinical Cancer Research 2004 10 24 8531 8537 (Pubitemid 40053420)
30. O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Sage E. H., Folkman J., Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 1994 79 2 315 328 (Pubitemid 24324921)
31. O'Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., Flynn E., Birkhead J. R., Olsen B. R., Folkman J., Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 1997 88 2 277 285 (Pubitemid 28015876)
32. Dhanabal M., Volk R., Ramchandran R., Simons M., Sukhatme V. P., Cloning, expression, and in vitro activity of human endostatin Biochemical and Biophysical Research Communications 1999 258 2 345 352 (Pubitemid 29287054)
33. Blezinger P., Wang J., Gondo M., Quezada A., Mehrens D., French M., Singhal A., Sullivan S., Rolland A., Ralston R., Min W., Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene Nature Biotechnology 1999 17 4 343 348 (Pubitemid 29166035)
34. Yoon S. S., Eto H., Lin C. M., Nakamura H., Pawlik T. M., Song S. U., Tanabe K. K., Mouse endostatin inhibits the formation of lung and liver metastases Cancer Research 1999 59 24 6251 6256 (Pubitemid 30035650)
35. Yokoyama Y., Dhanabal M., Griffioen A. W., Sukhatme V. P., Ramakrishnan S., Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth Cancer Research 2000 60 8 2190 2196 (Pubitemid 30225182)
36. Kisker O., Becker C. M., Prox D., Fannon M., D'Amato R., Flynn E., Fogler W. E., Sim B. K. L., Allred E. N., Pirie-Shepherd S. R., Folkman J., Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model Cancer Research 2001 61 20 7669 7674 (Pubitemid 32995064)
37. Shi W., Teschendorf C., Muzyczka N., Siemann D. W., Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo Cancer Gene Therapy 2002 9 6 513 521 (Pubitemid 34569034)
38. Feldman A. L., Alexander H. R., Hewitt S. M., Lorang D., Thiruvathukal C. E., Turner E. M., Libutti S. K., Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors Journal of the National Cancer Institute 2001 93 13 1014 1020 (Pubitemid 32677401)
39. Mundhenke C., Thomas J. P., Wilding G., Lee F. T., Kelzc F., Chappell R., Neider R., Sebree L. A., Friedl A., Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin Clinical Cancer Research 2001 7 11 3366 3374 (Pubitemid 33069967)
40. Eder J. P. Jr., Supko J. G., Clark J. W., Puchalski T. A., Garcia-Carbonero R., Ryan D. P., Shulman L. N., Proper J., Kirvan M., Rattner B., Connors S., Keogan M. T., Janicek M. J., Fogler W. E., Schnipper L., Kinchla N., Sidor C., Phillips E., Folkman J., Kufe D. W., Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily Journal of Clinical Oncology 2002 20 18 3772 3784
41. Herbst R. S., Hess K. R., Tran H. T., Tseng J. E., Mullani N. A., Charnsangavej C., Madden T., Davis D. W., McConkey D. J., O'Reilly M. S., Ellis L. M., Pluda J., Hong W. K., Abbruzzese J. L., Phase I study of recombinant human endostatin in patients with advanced solid tumors Journal of Clinical Oncology 2002 20 18 3792 3803
42. Thomas J. P., Arzoomanian R. Z., Alberti D., Marnocha R., Lee F., Friedl A., Tutsch K., Dresen A., Geiger P., Pluda J., Fogler W., Schiller J. H., Wilding G., Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors Journal of Clinical Oncology 2003 21 2 223 231 (Pubitemid 46606150)
43. Deschaseaux F., Sensébé L., Heymann D., Mechanisms of bone repair and regeneration Trends in Molecular Medicine 2009 15 9 417 429
44. Bjornland K., Flatmark K., Pettersen S., Aaasen A. O., Fodstad., Mlandsmo G. M., Matrix metalloproteinases participate in osteosarcoma invasion Journal of Surgical Research 2005 127 2 151 156 (Pubitemid 41080627)
45. Kansara M., Thomas D. M., Molecular pathogenesis of osteosarcoma DNA and Cell Biology 2007 26 1 1 18 (Pubitemid 46219587)
46. Fan D. G., Dai J. Y., Tang J., Wu M. M., Sun S. G., Jiang J. L., Fan Q. Y., Silencing of calpain expression reduces the metastatic potential of human osteosarcoma cells Cell Biology International 2009 33 12 1263 1267
47. Daz-Montero C. M., Wygant J. N., McIntyre B. W., PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation European Journal of Cancer 2006 42 10 1491 1500 (Pubitemid 43903158)
48. Hingorani P., Zhang W., Gorlick R., Kolb E. A., Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo Clinical Cancer Research 2009 15 10 3416 3422
49. Kim L. C., Song L., Haura E. B., Src kinases as therapeutic targets for cancer Nature Reviews Clinical Oncology 2009 6 10 587 595
50. Rubin E. M., Guo Y., Tu K., Xie J., Zi X., Hoang B. H., Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma Molecular Cancer Therapeutics 2010 9 3 731 741
51. Guo Y., Zi X., Koontz Z., Kim A., Xie J., Gorlick R., Holcombe R. F., Hoang B. H., Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells Journal of Orthopaedic Research 2007 25 7 964 971 (Pubitemid 47046444)
52. Engin F., Bertin T., Ma O., Jiang M. M., Wang L., Sutton R. E., Donehower L. A., Lee B., Notch signaling contributes to the pathogenesis of human osteosarcomas Human Molecular Genetics 2009 18 8 1464 1470
53. Hughes D. P. M., How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize Cancer Treatment and Research 2009 152 479 496
54. Tanaka M., Setoguchi T., Hirotsu M., Gao H., Sasaki H., Matsunoshita Y., Komiya S., Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation British Journal of Cancer 2009 100 12 1957 1965
55. Zhang P., Yang Y., Zweidler-McKay P. A., Hughes D. P. M., Critical role of notch signaling in osteosarcoma invasion and metastasis Clinical Cancer Research 2008 14 10 2962 2969
56. Soini Y., Satta J., Mtt M., Autio-Harmainen H., Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart The Journal of Pathology 2001 194 2 225 231
57. Kato Y., Yamashita T., Ishikawa M., Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells Oncology reports 2002 9 3 565 569
58. Lee P. P. H., Hwang J. J., Murphy G., Ip M. M., Functional significance of MMP-9 in tumor necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells Endocrinology 2000 141 10 3764 3773
59. Soreide K., Janssen E. A., Kmer H., Baak J. P. A., Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis Journal of Pathology 2006 209 2 147 156 (Pubitemid 43805409)
60. Cheng Y. Y., Huang L., Lee K. M., Li K., Kumta S. M., Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines Pediatric Blood and Cancer 2004 42 5 410 415 (Pubitemid 38524469)
61. Heikkila P., Teronen O., Hirn M. Y., Sorsa T., Tervahartiala T., Salo T., Konttinen Y. T., Halttunen T., Moilanen M., Hanemaaijer R., Laitinen M., Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate Journal of Surgical Research 2003 111 1 45 52 (Pubitemid 36814054)
62. Xin Z. F., Kim Y. K., Jung S. T., Risedronate inhibits human osteosarcoma cell invasion Journal of Experimental and Clinical Cancer Research 2009 28 1, article 105
63. Heymann D., Ory B., Gouin F., Green J. R., Rédini F., Bisphosphonates: new therapeutic agents for the treatment of bone tumors Trends in Molecular Medicine 2004 10 7 337 343 (Pubitemid 38881523)
64. Moriceau G., Ory B., Gobin B., Verrecchia F., Gouin F., Blanchard F., Redini F., Heymann D., Therapeutic approach of primary bone tumours by bisphosphonates Current Pharmaceutical Design 2010 16 27 2981 2987
65. Cho H. J., Lee T. S., Park J. B., Park K. K., Choe J. Y., Sin D. I., Park Y. Y., Moon Y. S., Lee K. G., Yeo J. H., Han S. M., Cho Y. S., Choi M. R., Park N. G., Lee Y. S., Chang Y. C., Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression Journal of Biochemistry and Molecular Biology 2007 40 6 1069 1076
66. Macsai C. E., Foster B. K., Xian C. J., Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair Journal of Cellular Physiology 2008 215 3 578 587 (Pubitemid 351632678)
67. Glass D. A., Bialek P., Ahn J. D., Starbuck M., Patel M. S., Clevers H., Taketo M. M., Long F., McMahon A. P., Lang R. A., Karsenty G., Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation Developmental Cell 2005 8 5 751 764 (Pubitemid 40585297)
68. Kawano Y., Kypta R., Secreted antagonists of the Wnt signalling pathway Journal of Cell Science 2003 116 13 2627 2634 (Pubitemid 36857216)
69. Baron R., Rawadi G., Minireview: targeting the Wnt/ -catenin pathway to regulate bone formation in the adult skeleton Endocrinology 2007 148 6 2635 2643 (Pubitemid 46984775)
70. Canalis E., Giustina A., Bilezikian J. P., Mechanisms of anabolic therapies for osteoporosis The New England Journal of Medicine 2007 357 9 850 916
71. Hsieh J. C., Kodjabachian L., Rebbert M. L., Rattner A., Smallwood P. M., Samos C. H., Nusse R., Dawid I. B., Nathans J., A new secreted protein that binds to Wnt proteins and inhibits their activites Nature 1999 398 6726 431 436 (Pubitemid 29180376)
72. Tetsu O., McCormick F., -catenin regulates expression of cyclin D1 in colon carcinoma cells Nature 1999 398 6726 422 426 (Pubitemid 29180374)
73. He T. C., Sparks A. B., Rago C., Hermeking H., Zawel L., Da Costa L. T., Morin P. J., Vogelstein B., Kinzler K. W., Identification of c-MYC as a target of the APC pathway Science 1998 281 5382 1509 1512 (Pubitemid 28425575)
74. Crawford H. C., Fingleton B. M., Rudolph-Owen L. A., Heppner Goss K. J., Rubinfeld B., Polakis P., Matrisian L. M., The metalloproteinase matrilysin is a target of -catenin transactivation in intestinal tumors Oncogene 1999 18 18 2883 2891 (Pubitemid 29250878)
75. Kim P. J., Plescia J., Clevers H., Fearon E. R., Altieri D. C., Survivin and molecular pathogenesis of colorectal cancer The Lancet 2003 362 9379 205 209 (Pubitemid 36859937)
76. Haydon R. C., Deyrup A., Ishikawa A., Heck R., Jiang W., Zhou L., Feng T., King D., Cheng H., Breyer B., Peabody T., Simon M. A., Montag A. G., He T. C., Cytoplasmic and/or nuclear accumulation of the -catenin protein is a frequent event in human osteosarcoma International Journal of Cancer 2002 102 4 338 342 (Pubitemid 35265873)
77. Iwaya K., Ogawa H., Kuroda M., Izumi M., Ishida T., Mukai K., Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis Clinical and Experimental Metastasis 2003 20 6 525 529 (Pubitemid 37297180)
78. Iwao K., Miyoshi Y., Nawa G., Yoshikawa H., Ochi T., Nakamura Y., Frequent -catenin abnormalities in bone and soft-tissue tumors Japanese Journal of Cancer Research 1999 90 2 205 209 (Pubitemid 29112321)
79. Hoang B. H., Kubo T., Healey J. H., Sowers R., Mazza B., Yang R., Huvos A. G., Meyers P. A., Gorlick R., Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma International Journal of Cancer 2004 109 1 106 111 (Pubitemid 38160669)
80. Hoang B. H., Kubo T., Healey J. H., Yang R., Nathan S. S., Kolb E. A., Mazza B., Meyers P. A., Gorlick R., Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt- -catenin pathway Cancer Research 2004 64 8 2734 2739 (Pubitemid 38500609)
81. Polakis P., Wnt signaling and cancer Genes and Development 2000 14 15 1837 1851 (Pubitemid 30639518)
82. Leow P. C., Tian Q., Ong Z. Y., Yang Z., Ee P. L. R., Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/ -catenin antagonists against human osteosarcoma cells Investigational New Drugs 2010 28 6 766 782
83. Mazieres J., He B., You L., Xu Z., Lee A. Y., Mikami I., Reguart N., Rosell R., McCormick F., Jablons D. M., Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer Cancer Research 2004 64 14 4717 4720 (Pubitemid 38924512)
84. Lin Y. C., You L., Xu Z., He B., Mikami I., Thung E., Chou J., Kuchenbecker K., Kim J., Raz D., Yang C. T., Chen J. K., Jablons D. M., Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines Biochemical and Biophysical Research Communications 2006 341 2 635 640 (Pubitemid 43152150)
85. Ai L., Tao Q., Zhong S., Fields C. R., Kim W. J., Lee M. W., Cui Y., Brown K. D., Robertson K. D., Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer Carcinogenesis 2006 27 7 1341 1348 (Pubitemid 43985409)
86. Yamashita S., Tsujino Y., Moriguchi K., Tatematsu M., Ushijima T., Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza- 2′ -deoxycytidine treatment and oligonucleotide microarray Cancer Science 2006 97 1 64 71 (Pubitemid 43257029)
87. Artavanis-Tsakonas S., Rand M. D., Lake R. J., Notch signaling: cell fate control and signal integration in development Science 1999 284 5415 770 776 (Pubitemid 29291335)
88. Kopan R., Ilagan M. X., The canonical notch signaling pathway: unfolding the activation mechanism Cell 2009 137 2 216 233
89. Iso T., Kedes L., Hamamori Y., HES and HERP families: multiple effectors of the Notch signaling pathway Journal of Cellular Physiology 2003 194 3 237 255 (Pubitemid 36176887)
90. Maa M. C., Leu T. H., Mccarley D. J., Schatzman R. C., Parsons S. J., Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers Proceedings of the National Academy of Sciences of the United States of America 1995 92 15 6981 6985
91. Mori S., Ronnstrand L., Yokote K., Engstrom A., Courtneidge S. A., Claesson-Welsh L., Heldin C. H., Identification of two juxtamembrane autophosphorylation sites in the PGDF -receptor; Involvement in the interaction with Src family tyrosine kinases The EMBO Journal 1993 12 6 2257 2264 (Pubitemid 23194175)
92. Playford M. P., Schaller M. D., The interplay between Src and integrins in normal and tumor biology Oncogene 2004 23 48 7928 7946 (Pubitemid 39468852)
93. Talpaz M., Shah N. P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., Blackwood-Chirchir M. A., Iyer V., Chen T. T., Huang F., Decillis A. P., Sawyers C. L., Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias The New England Journal of Medicine 2006 354 24 2531 2541 (Pubitemid 43882349)
94. Johnson F. M., Saigal B., Talpaz M., Donato N. J., Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells Clinical Cancer Research 2005 11 19, part 1 6924 6932 (Pubitemid 41428750)
95. Schittenhelm M. M., Shiraga S., Schroeder A., Corbin A. S., Griffith D., Lee F. Y., Bokemeyer C., Deininger M. W. N., Druker B. J., Heinrich M. C., Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies Cancer Research 2006 66 1 473 481 (Pubitemid 43166056)
96. Shor A. C., Keschman E. A., Lee F. Y., Muro-Cacho C., Letson G. D., Trent J. C., Pledger W. J., Jove R., Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival Cancer Research 2007 67 6 2800 2808 (Pubitemid 46548969)
97. Owen-Schaub L. B., Van Golen K. L., Hill L. L., Price J. E., Fas and Fas ligand interactions suppress melanoma lung metastasis Journal of Experimental Medicine 1998 188 9 1717 1723 (Pubitemid 28516116)
98. Sayers T. J., Brooks A. D., Lee J. K., Fenton R. G., Komschlies K. L., Wigginton J. M., Winkler-Pickett R., Wiltrout R. H., Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus fas-mediated pathways in lysis by NK and T cells Journal of Immunology 1998 161 8 3957 3965 (Pubitemid 28468972)
99. Lee J. K., Sayers T. J., Brooks A. D., Back T. C., Young H. A., Komschlies K. L., Wigginton J. M., Wiltrout R. H., IFN- -dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells Journal of Immunology 2000 164 1 231 239 (Pubitemid 30012995)
100. Gordon N., Arndt C. A., Hawkins D. S., Doherty D. K., Inwards C. Y., Munsell M. F., Stewart J., Koshkina N. V., Kleinerman E. S., Fas expression in lung metastasis from osteosarcoma patients Journal of Pediatric Hematology/Oncology 2005 27 11 611 615 (Pubitemid 41697350)
101. Worth L. L., Lafleur E. A., Jia S. F., Kleinerman E. S., Fas expression inversely correlates with metastatic potential in osteosarcoma cells Oncology Reports 2002 9 4 823 827
102. Peter M. E., Budd R. C., Desbarats J., Hedrick S. M., Hueber A. O., Newell M. K., Owen L. B., Pope R. M., Tschopp J., Wajant H., Wallach D., Wiltrout R. H., Zrnig M., Lynch D. H., The CD95 receptor: apoptosis revisited Cell 2007 129 3 447 450 (Pubitemid 46660984)
103. Chen L., Park S. M., Tumanov A. V., Hau A., Sawada K., Feig C., Turner J. R., Fu Y. X., Romero I. L., Lengyel E., Peter M. E., CD95 promotes tumour growth Nature 2010 465 7297 492 496
104. Strasser A., Jost P. J., Nagata S., The many roles of FAS receptor signaling in the immune system Immunity 2009 30 2 180 192
105. Igney F. H., Krammer P. H., Death and anti-death: tumour resistance to apoptosis Nature Reviews Cancer 2002 2 4 277 288 (Pubitemid 37328781)
106. Gorlick R., Anderson P., Andrulis I., Arndt C., Beardsley G. P., Bernstein M., Bridge J., Cheung N. K., Dome J. S., Ebb D., Gardner T., Gebhardt M., Grier H., Hansen M., Healey J., Helman L., Hock J., Houghton J., Houghton P., Huvos A., Khanna C., Kieran M., Kleinerman E., Ladanyi M., Lau C., Malkin D., Marina N., Meltzer P., Meyers P., Schofield D., Schwartz C., Smith M. A., Toretsky J., Tsokos M., Wexler L., Wigginton J., Withrow S., Schoenfeldt M., Anderson B., Biology of ghildhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary Clinical Cancer Research 2003 9 15 5442 5453 (Pubitemid 37499462)
107. Koshkina N. V., Khanna C., Mendoza A., Guan H., DeLauter L., Kleinerman E. S., Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the fas pathwayin the metastatic process of osteosarcoma Molecular Cancer Research 2007 5 10 991 999 (Pubitemid 350070755)
108. Lafleur E. A., Jia S. F., Worth L. L., Zhou Z., Owen-Schaub L. B., Kleinerman E. S., Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells Cancer Research 2001 61 10 4066 4071 (Pubitemid 32720972)
109. Lafleur E. A., Koshkina N. V., Stewart J., Jia S. F., Worth L. L., Duan X., Kleinerman E. S., Increased Fas expression reduces the metastatic potential of human osteosarcoma cells Clinical Cancer Research 2004 10 23 8114 8119 (Pubitemid 39587553)
110. Zhou Z., Lafleur E. A., Koshkina N. V., Worth L. L., Lester M. S., Kleinerman E. S., Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity Molecular Cancer Research 2005 3 12 685 691 (Pubitemid 43042998)
111. Duan X., Jia S. F., Koshkina N., Kleinerman E. S., Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases Cancer 2006 106 6 1382 1388 (Pubitemid 43363918)
112. Mori K., Ando K., Heymann D., Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases Expert Review of Anticancer Therapy 2008 8 2 151 159 (Pubitemid 351385905)
113. Lebel-Binay S., Berger A., Zinzindohoué F., Cugnene P. H., Thiounn N., Fridman W. H., Pags F., Interleukin-18: biological properties and clinical implications European Cytokine Network 2000 11 1 15 25 (Pubitemid 30145398)
114. Golab J., Interleukin 18Interferon inducing factora novel player in tumour immunotherapy? Cytokine 2000 12 4 332 338 (Pubitemid 30449823)
115. Cao R., Farnebo J., Kurimoto M., Cao Y., Interleukin-18 acts as an angiogenesis and tumor suppressor The FASEB Journal 1999 13 15 2195 2202
116. Ohtsuki T., Micallef M. J., Kohno K., Tanimoto T., Ikeda M., Kurimoto M., Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells Anticancer Research 1997 17 5 3253 3258 (Pubitemid 27522278)
117. Nakamura Y., Yamada N., Ohyama H., Nakasho K., Nishizawa Y., Okamoto T., Futani H., Yoshiya S., Okamura H., Terada N., Effect of interleukin-18 on metastasis of mouse osteosarcoma cells Cancer Immunology, Immunotherapy 2006 55 9 1151 1158 (Pubitemid 43800730)
118. Yamada N., Hata M., Ohyama H., Yamanegi K., Kogoe N., Nakasho K., Futani H., Okamura H., Terada N., Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model Tumor Biology 2009 30 4 176 184
119. Boudreau N., Sympson C. J., Werb Z., Bissell M. J., Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix Science 1995 267 5199 891 893
120. Grossmann J., Walther K., Artinger M., Kiessling S., Schlmerich J., Apoptotic signaling during initiation of detachment-induced apoptosis ("anoikis") of primary human intestinal epithelial cells Cell Growth and Differentiation 2001 12 3 147 155 (Pubitemid 32678000)
121. Frisch S. M., Screaton R. A., Anoikis mechanisms Current Opinion in Cell Biology 2001 13 5 555 562 (Pubitemid 32817013)
122. Diaz-Montero C. M., McIntyre B. W., Acquisition of anoikis resistance in human osteosarcoma cells European Journal of Cancer 2003 39 16 2395 2402 (Pubitemid 37214865)
123. Liotta L. A., Kohn E., Anoikis: cancer and the homeless cell Nature 2004 430 7003 973 974
124. Mehlen P., Puisieux A., Metastasis: a question of life or death Nature Reviews Cancer 2006 6 6 449 458
125. Trusolino L., Bertotti A., Comoglio P. M., A signaling adapter function for 6 4 integrin in the control of HGF-dependent invasive growth Cell 2001 107 5 643 654 (Pubitemid 34014865)
126. Nikolopoulos S. N., Blaikie P., Yoshioka T., Guo W., Giancotti F. G., Integrin 4 signaling promotes tumor angiogenesis Cancer Cell 2004 6 5 471 483 (Pubitemid 39469983)
127. Guo W., Pylayeva Y., Pepe A., Yoshioka T., Muller W. J., Inghirami G., Giancotti F. G., 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis Cell 2006 126 3 489 502 (Pubitemid 44163602)
128. Wan X., Kim S. Y., Guenther L. M., Mendoza A., Briggs J., Yeung C., Currier D., Zhang H., MacKall C., Li W. J., Tuan R. S., Deyrup A. T., Khanna C., Helman L., Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin Oncogene 2009 28 38 3401 3411
129. Chiarugi P., Giannoni E., Anoikis: a necessary death program for anchorage-dependent cells Biochemical Pharmacology 2008 76 11 1352 1364
130. Janes S. M., Watt F. M., Switch from v 5 to v 6 integrin expression protects squamous cell carcinomas from anoikis Journal of Cell Biology 2004 166 3 419 431 (Pubitemid 39031244)
131. Stan R. V., Structure of caveolae Biochimica et Biophysica Acta 2005 1746 3 334 348 (Pubitemid 41815027)
132. Rothberg K. G., Heuser J. E., Donzell W. C., Ying Y. S., Glenney J. R., Anderson R. G. W., Caveolin, a protein component of caveolae membrane coats Cell 1992 68 4 673 682
133. Solomon K. R., Danciu T. E., Adolphson L. D., Hecht L. E., Hauschka P. V., Caveolin-enriched membrane signaling complexes in human and murine osteoblasts Journal of Bone and Mineral Research 2000 15 12 2380 2390
134. Cantiani L., Manara M. C., Zucchini C., De Sanctis P., Zuntini M., Valvassori L., Serra M., Olivero M., Di Renzo M. F., Colombo M. P., Picci P., Scotlandi K., Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling Cancer Research 2007 67 16 7675 7685 (Pubitemid 47281360)
135. Al-Mehdi A. B., Tozawa K., Fisher A. B., Shientag L., Lee A., Muschel R. J., Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis Nature Medicine 2000 6 1 100 102 (Pubitemid 30048535)
136. Jeffree G. M., Price C. H., Sissons H. A., The metastatic patterns of osteosarcoma British Journal of Cancer 1975 32 1 87 107
137. Lin F., Zheng S.-E., Shen Z., Tang L.-N., Chen P., Sun Y.-J., Zhao H., Yao Y., Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma Medical Oncology 2011 28 2 649 653
138. Laverdiere C., Hoang B. H., Yang R., Sowers R., Qin J., Meyers P. A., Huvos A. G., Healey J. H., Gorlick R., Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma Clinical Cancer Research 2005 11 7 2561 2567 (Pubitemid 40569454)
139. Huang C. Y., Lee C. Y., Chen M. Y., Yang W. H., Chen Y. H., Chang C. H., Hsu H. C., Fong Y. C., Tang C. H., Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF- B-dependent pathways Journal of Cellular Physiology 2009 221 1 204 212
140. Murphy P. M., Chemokines and the molecular basis of cancer metastasis The New England Journal of Medicine 2001 345 11 833 835
141. Mller A., Homey B., Soto H., Ge N., Catron D., Buchanan M. E., McClanahan T., Murphy E., Yuan W., Wagner S. N., Barrera J. L., Mohar A., Verstegui E., Zlotnik A., Involvement of chemokine receptors in breast cancer metastasis Nature 2001 410 6824 50 56 (Pubitemid 32225831)
142. Murakami T., Maki W., Cardones A. R., Fang H., Tun Kyi A., Nestle F. O.,
143. Scotton C. J., Wilson J. L., Scott K., Stamp G., Wilbanks G. D., Fricker S., Bridger G., Balkwill F. R., Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer Cancer Research 2002 62 20 5930 5938 (Pubitemid 35204756)
144. Pradelli E., Karimdjee-Soilihi B., Michiels J. F., Ricci J. E., Millet M. A., Vandenbos F., Sullivan T. J., Collins T. L., Johnson M. G., Medina J. C., Kleinerman E. S., Schmid-Alliana A., Schmid-Antomarchi H., Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs International Journal of Cancer 2009 125 11 2586 2594
145. de Nigris F., Rossiello R., Schiano C., Arra C., Williams-Ignarro S., Barbieri A., Lanza A., Balestrieri A., Giuliano M. T., Ignarro L. J., Napoli C., Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis Cancer Research 2008 68 6 1797 1808 (Pubitemid 351416565)
146. Robledo M. M., Bartolomé R. A., Longo N., Rodriguez-Frade J. M., Mellado M., Longo I., Van Muijen G. N. P., Snchez-Mateos P., Teixid J., Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells Journal of Biological Chemistry 2001 276 48 45098 45105
147. Jones D., Benjamin R. J., Shahsafaei A., Dorfman D. M., The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia Blood 2000 95 2 627 632 (Pubitemid 30041679)
148. Goldberg-Bittman L., Neumark E., Sagi-Assif O., Azenshtein E., Meshel T., Witz I. P., Ben-Baruch A., The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines Immunology Letters 2004 92 1-2 171 178 (Pubitemid 38470065)
149. Mangeat P., Roy C., Martin M., ERM proteins in cell adhesion and membrane dynamics Trends in Cell Biology 1999 9 5 187 192 (Pubitemid 29192986)
150. Hirao M., Sato N., Kondo T., Yonemura S., Monden M., Sasaki T., Takai Y., Tsukita S., Tsukita S., Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and rho-dependent signaling pathway Journal of Cell Biology 1996 135 1 37 51 (Pubitemid 26337735)
151. Gautreau A., Poullet P., Louvard D., Arpin M., Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway Proceedings of the National Academy of Sciences of the United States of America 1999 96 13 7300 7305 (Pubitemid 29299656)
152. Hunter K. W., Ezrin, a key component in tumor metastasis Trends in Molecular Medicine 2004 10 5 201 204 (Pubitemid 38581790)
153. Ilmonen S., Vaheri A., Asko-Seljavaara S., Carpen O., Ezrin in primary cutaneous melanoma Modern Pathology 2005 18 4 503 510 (Pubitemid 40478113)
154. Weng W. H., hlén J., strm K., Lui W. O., Larsson C., Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas Clinical Cancer Research 2005 11 17 6198 6204 (Pubitemid 41262948)
155. Khanna C., Wan X., Bose S., Cassaday R., Olomu O., Mendoza A., Yeung C., Gorlick R., Hewitt S. M., Helman L. J., The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis Nature Medicine 2004 10 2 182 186 (Pubitemid 38524889)
156. Ren L., Hong S. H., Cassavaugh J., Osborne T., Chou A. J., Gorlick R., Hewitt S. M., Khanna C., The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC Oncogene 2009 28 6 792 802
157. Khanna C., Khan J., Nguyen P., Prehn J., Caylor J., Yeung C., Trepel J., Meltzer P., Helman L., Metastasis-associated differences in gene expression in a murine model of osteosarcoma Cancer Research 2001 61 9 3750 3759 (Pubitemid 32694989)
158. Ikeda S., Sumii H., Akiyama K., Watanabe S., Ito S., Inoue H., Takechi H., Tanabe G., Oda T., Amplification of both c-myc and c-raf-1 oncogenes in a human osteosarcoma Japanese Journal of Cancer Research 1989 80 1 6 9 (Pubitemid 20027190)
159. Wilhelm S. M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L. E., Bollag G., Trail P. A., BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Research 2004 64 19 7099 7109 (Pubitemid 39331023)
160. Pignochino Y., Grignani G., Cavalloni G., Motta M., Tapparo M., Bruno S., Bottos A., Gammaitoni L., Migliardi G., Camussi G., Alberghini M., Torchio B., Ferrari S., Bussolino F., Fagioli F., Picci P., Aglietta M., Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways Molecular Cancer 2009 8, article 118
161. Hesse V., Jahreis G., Schambach H., Vogel H., Vilser C., Seewald H. J., Borner A., Deichl A., Insulin-like growth factor I correlations to changes of the hormonal status in puberty and age Experimental and Clinical Endocrinology 1994 102 4 289 298
162. Kawai N., Kanzaki S., Takano-Watou S., Tada C., Yamanaka Y., Miyata T., Oka M., Seino Y., Serum free insulin-like growth factor I (IGF-I), total IGF-I, and IGF- binding protein-3 concentrations in normal children and children with growth hormone deficiency Journal of Clinical Endocrinology and Metabolism 1999 84 1 82 89 (Pubitemid 29036684)
163. Herzlieb N., Gallaher B. W., Berthold A., Hille R., Kiess W., Insulin-like growth factor-I inhibits the progression of human U-2 OS osteosarcoma cells towards programmed cell death through interaction with the IGF-I receptor Cellular and Molecular Biology 2000 46 1 71 77
164. Kappel C. C., Velez-Yanguas M. C., Hirschfeld S., Helman L. J., Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth Cancer Research 1994 54 10 2803 2807 (Pubitemid 24173778)
165. Pollak M., Sem A. W., Richard M., Tetenes E., Bell R., Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy Journal of the National Cancer Institute 1992 84 12 966 971
166. Mansky P. J., Liewehr D. J., Steinberg S. M., Chrousos G. P., Avila N. A., Long L., Bernstein D., Mackall C. L., Hawkins D. S., Helman L. J., Treatment of metastatic osteosarcoma with the somatostatin analog oncoLar: significant reduction of insulin-like growth factor-1 serum levels Journal of Pediatric Hematology/Oncology 2002 24 6 440 446
167. Khanna C., Prehn J., Hayden D., Cassaday R. D., Caylor J., Jacob S., Bose S. M., Hong S. H., Hewitt S. M., Helman L. J., A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy Clinical Cancer Research 2002 8 7 2406 2412 (Pubitemid 34753616)
168. Wang Y. H., Wang Z. X., Qiu Y., Xiong J., Chen Y. X., Miao D. S., De W., Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells Molecular and Cellular Biochemistry 2009 327 1-2 257 266
169. Wang Y. H., Xiong J., Wang S. F., Yu Y., Wang B., Chen Y. X., Shi H. F., Qiu Y., Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo Molecular and Cellular Biochemistry 2010 341 1-2 225 233
170. Kolb E. A., Gorlick R., Houghton P. J., Morton C. L., Lock R., Carol H., Patrick Reynolds C., Maris J. M., Keir S. T., Billups C. A., Smith M. A., Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program Pediatric Blood and Cancer 2008 50 6 1190 1197 (Pubitemid 351555543)
171. Kolb E. A., Kamara D., Zhang W., Lin J., Hingorani P., Baker L., Houghton P., Gorlick R., R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts Pediatric Blood and Cancer 2010 55 1 67 75
172. Wang Y. H., Han X. D., Qiu Y., Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma Journal of Surgical Oncology 2012 105 3 235 243
173. Pantel K., Brakenhoff R. H., Dissecting the metastatic cascade Nature Reviews Cancer 2004 4 6 448 456 (Pubitemid 38745530)
174. Aguirre-Ghiso J. A., Models, mechanisms and clinical evidence for cancer dormancy Nature Reviews Cancer 2007 7 11 834 846 (Pubitemid 350006258)
175. Naumov G. N., Townson J. L., MacDonald I. C., Wilson S. M., Bramwell V. H. C., Groom A. C., Chambers A. F., Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases Breast Cancer Research and Treatment 2003 82 3 199 206 (Pubitemid 37521976)
176. Holmgren L., O'Reilly M. S., Folkman J., Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression Nature Medicine 1995 1 2 149 153
177. Wikman H., Vessella R., Pantel K., Cancer micrometastasis and tumour dormancy APMIS 2008 116 7-8 754 770
178. Naumov G. N., Bender E., Zurakowski D., Kang S. Y., Sampson D., Flynn E., Watnick R. S., Straume O., Akslen L. A., Folkman J., Almog N., A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype Journal of the National Cancer Institute 2006 98 5 316 325 (Pubitemid 43338211)
179. Cao Y., O'Reilly M. S., Marshall B., Flynn E., Ji R. W., Folkman J., Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases Journal of Clinical Investigation 1998 101 5 1055 1063 (Pubitemid 28125284)
180. Favaro E., Amadori A., Indraccolo S., Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy APMIS 2008 116 7-8 648 659
181. Barkan D., Green J. E., Chambers A. F., Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth European Journal of Cancer 2010 46 7 1181 1188
182. Koebel C. M., Vermi W., Swann J. B., Zerafa N., Rodig S. J., Old L. J., Smyth M. J., Schreiber R. D., Adaptive immunity maintains occult cancer in an equilibrium state Nature 2007 450 7171 903 907 (Pubitemid 350231320)